Regeneron Pharmaceuticals Inc 2020 AR2
The report highlights Regeneron's response to the COVID-19 pandemic in 2020, including the rapid development and manufacturing of the REGEN-COV antibody cocktail. Financially, the company achieved 30 percent top-line growth, with total revenues reaching $8.5 billion, driven by products like EYLEA and Dupixent. Regeneron also advanced its clinical pipeline to 30 investigational medicines and established a dedicated hematology therapeutic area. Additionally, the company expanded its corporate responsibility efforts, publishing its first TCFD-aligned climate report and continuing alignment with SASB standards.
Company: Regeneron Pharmaceuticals Inc
Sector: Manufacturing
Country: United States
Year: 2020
Type: AR2
Pages: 39
Back to company
Regeneron Pharmaceuticals Inc
Annual Report
The report highlights Regeneron's response to the COVID-19 pandemic in 2020, including the rapid development and manufacturing of the REGEN-COV antibody cocktail. Financially, the company achieved 30 percent top-line growth, with total revenues reaching $8.5 billion, driven by products like EYLEA and Dupixent. Regeneron also advanced its clinical pipeline to 30 investigational medicines and established a dedicated hematology therapeutic area. Additionally, the company expanded its corporate responsibility efforts, publishing its first TCFD-aligned climate report and continuing alignment with SASB standards.
Sign in for free to access detailed sustainability data, reporting standards, and ESG metrics.
Document Details
Report Year
2020
Reporting Period
Jan 1, 2020 - Dec 31, 2020
Fiscal Year
2020
Type
Annual Report with Sustainability Disclosures
Language
English
Pages
File Size
Standards & Assurance
Reporting Standards
ESG Data?Experimental: AI-extracted data, may contain inaccuracies
Employees